Hands working on a medical device

SPP-ARC

Striving for Pandemic Preparedness —
The Alberta Research Consortium

The concept behind the logo is the destruction of a virus by a spark representing effective vaccines and antiviral drugs.

Enabling rapid responses to emerging pathogens

The University of Alberta has made substantial investments to support research and training in infectious diseases. The available resources have been instrumental in Alberta's scientific response to the COVID-19 pandemic. In spite of progress, it is evident that our preparedness for the next pandemic needs to be improved. The Government of Alberta awarded the University of Alberta a $55.1 M grant to develop a pandemic preparedness program. With this grant, scientists at the University of Alberta are building capacity in this area and founded SPP-ARC: Striving for Pandemic Preparedness – The Alberta Research Consortium.

MISSION

Prepare for Pandemics

Establish capabilities to discover, develop and assess vaccines and antivirals for better protection against emerging pathogens

VISION

Enable Rapid Responses

Support clinical trials and the approval of effective medical countermeasures in the next pandemic

 

A Pipeline Approach

Nobody can predict the time and/or nature of the next pandemic. So what can we do to prepare for the worst? SPP-ARC aims to create a home-grown pipeline for the development of vaccines and antiviral drugs against priority pathogens, such as coronaviruses and influenza viruses. The goal is to establish capabilities that enable rapid responses to emerging threats.

Research and Training

Pandemic preparedness requires ongoing, interdisciplinary research efforts and partnerships. SPP-ARC investigators cover a broad range of complementary expertise in the areas of virology, immunology, biochemistry, medicinal chemistry and structural biology. A comprehensive research program from discovery to manufacturing provides an ideal environment for the training of highly qualified personnel (HQP).

Enhancing Infrastructure

The establishment of a transformative structural biology core with a state-of-the-art Cryo-Electron Microscopy platform will support the design of vaccines and therapeutics. One of the largest Biosafety Level-3 (BSL-3) facilities in the country supports preclinical studies, and the Alberta Cell Therapy Manufacturing facility (ACTM) will provide fill-finish production capabilities.
SPP-ARC Events

Visit our Events page to hear about our upcoming scientific meetings, seminars, and retreats!

SPP-ARC Events